Up Day as Wall Stre...
Health Care: Drugs
iBio Inc. (IBIO: AMEX)
$0.44 0.01 | 2.09%
06/17/13 - 04:01 PM ET
Company Balance Sheet
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 5.62M | 2.84M | 909.93K | 1.04M |
| Receivables | 351.41K | 344.08K | 47.46K | 210.00K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 239.90K | 349.21K | 0.00 | 17.00K |
| Total Current Assets | 6.90M | 4.30M | 1.03M | 1.27M |
| Property, Plant & Equipment, Gross | 2.50K | 8.41K | 11.05K | 15.00K |
| Accumulated Depreciation & Depletion | 0.00 | 0.00 | 0.00 | 0.00 |
| Property, Plant & Equipment, Net | 2.50K | 8.41K | 11.05K | 15.00K |
| Intangibles | 2.86M | 3.03M | 3.89M | 3.65M |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Assets | 2.86M | 3.04M | 3.90M | 3.66M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 9.76M | 7.34M | 4.93M | 4.93M |
| Accounts Payable | 2.85M | 2.90M | 2.01M | 112.00K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 519.72K | 4.19M | 1.71M | 0.00 |
| Total Current Liabilities | 3.60M | 7.14M | 3.85M | 542.00K |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.60M | 7.14M | 3.85M | 542.00K |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 6.17M | 196.64K | 1.08M | 4.39M |
| Common Par | 47.77K | 32.38K | 28.27K | 0.00 |
| Additional Paid In Capital | 37.46M | 25.83M | 14.57M | 13.07M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -31.34M | -25.66M | -13.52M | -8.68M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 6.17M | 196.64K | 1.08M | 4.39M |
| Total Equity | 6.17M | 196.64K | 1.08M | 4.39M |
| Total Liabilities & Stock Equity | 9.76M | 7.34M | 4.93M | 4.93M |
| Total Common Shares Outstanding | 47.77M | 32.38M | 28.27M | 23.36M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 39.51M | 30.97M | 27.30M | 20.27M |
| Diluted Weighted Shares Outstanding | 39.51M | 30.97M | 27.30M | 20.27M |
| Number of Employees | 7 | 7 | 3 | 2 |
| Number of Part-Time Employees | 0 | 0 | 2 | 1 |
Portfolios with IBIO
- Portfolio NameUser Type
- Usercosmo
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
Latest IBIO Headlines from TheStreet
- 4 Biotech Stocks Under $10 Moving Higher 10.05.12 | 08:10 am
- 5 Stocks Under $10 Setting Up to Break Out 09.13.12 | 12:09 pm
- 10 New Stocks Rated by TheStreet 08.03.11 | 02:08 pm
Press Releases for IBIO
- GE Alliance Awarded Contract To Design New Plant-based Manufacturing Facility In Brazil - PR Newswire 04.09.13 | 07:04 am
- IBio Selects Proprietary Recombinant C1 Inhibitor For Clinical Development - PR Newswire 03.26.13 | 07:03 am
- IBio Adds To IBioModulator Portfolio And Product Pipeline - PR Newswire 03.13.13 | 07:03 am
- IBio Adds New Therapeutic Antibody To Its Pipeline - PR Newswire 03.04.13 | 09:03 am
- IBio, Inc. Receives Anticipated Notice From NYSE MKT That Company Is Below Certain Continued Listing Standards - PR Newswire 03.04.13 | 09:03 am
- IBio And Caliber Biotherapeutics Establish License And Collaboration Relationship - PR Newswire 02.19.13 | 07:02 am
- IBio, Inc. Receives Approval From NYSE MKT Of Compliance Plan - PR Newswire 02.13.13 | 07:02 am
- IBio Announces At-the-Market Equity Offering - PR Newswire 02.01.13 | 09:02 am
- IBio Announces New Appointment To Board Of Directors And New Addition To Executive Management Team - PR Newswire 12.21.12 | 07:12 am
- National Institute Of Health Awards Contract To Support Use Of IBio's Proprietary Technology For Improved Anthrax Vaccine - PR Newswire 12.05.12 | 07:12 am
Partner Headlines for IBIO
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- Rituxan And Its Biosimilar Competitors - Seeking Alpha 07.30.12 | 09:07 am
- iBio Announces Proposed Public Offering; No Amount Given - Benzinga 01.09.12 | 04:01 pm
- IBIO: Pharma Stock With Much Downside Risk And Low Upside Potential - Seeking Alpha 11.02.11 | 08:11 am
- iBio Still Overvalued; More Dilution Likely - Seeking Alpha 06.29.11 | 09:06 am
- Trading Resumes: iBio, Inc. - Benzinga 03.08.11 | 01:03 pm
- iBio Overvalued - Seeking Alpha 02.09.11 | 08:02 am
- 4 Stocks for the Aggressive Investor - Seeking Alpha 02.02.11 | 08:02 am
- iBio: A True Paradigm Shift - Seeking Alpha 01.24.11 | 09:01 am
